TARGETED DEGRADATION OF VAV1

Abstract: this disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades proto-oncogene vav protein (vav). the chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.

Inventor(s): Laura Ann McAllister, Elisa Liardo, Andreas Ritzen, Vladimiras Oleinikovas, Xavier Lucas Cabré, Bernhard Fasching, Lorenzo Delarue Bizzini, Mathieu Lesieur

CPC Classification: A61K31/4545 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250205219